Protective effect of carnosine on white matter damage in corpus striatum induced by chronic cerebral hypoperfusion

Neurosci Lett. 2018 Sep 14:683:54-60. doi: 10.1016/j.neulet.2018.06.032. Epub 2018 Jun 19.

Abstract

Subcortical ischemic vascular dementia caused by chronic cerebral hypoperfusion due to small-artery disease is a common subtype of vascular dementia, which is recognized as the second most prevalent type of dementia. The aim of this study was to determine the effect of carnosine on white matter damage in corpus striatum. Adult male mice (C57BL/6 strain) were subjected to right unilateral common carotid arteries occlusion (rUCCAO), and treated with carnosine or saline. Klüver-Barrera staining, immunohistochemical analyses, Western blots and neurochemical analysis were performed after rUCCAO. The white matter in corpus striatum was damaged at day 37 after rUCCAO, which was largely rescued by carnosine (200, 500 mg/kg). Carnosine (200, 500 mg/kg) significantly recovered the expression of myelin basic protein, suppressed the activation of microglia and reversed the decrease of 5-hydroxytryptamine and dopamine levels in corpus striatum. Moreover, carnosine (200, 500 mg/kg) significantly inhibited the apoptosis in corpus striatum. These data suggest that carnosine has the neuroprotective effect in corpus striatum on rUCCAO in mice, may be due to its protection of neurotransmitters and inhibition of apoptosis.

Keywords: Carnosine; Corpus striatum; Microglia; Subcortical ischemic vascular dementia; White matter damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carnosine / pharmacology
  • Carnosine / therapeutic use*
  • Carotid Artery Diseases / pathology
  • Carotid Artery Diseases / prevention & control*
  • Cerebrovascular Circulation / drug effects*
  • Cerebrovascular Circulation / physiology
  • Corpus Striatum / drug effects*
  • Corpus Striatum / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • White Matter / drug effects*
  • White Matter / pathology

Substances

  • Neuroprotective Agents
  • Carnosine